Navigation Links
FDA Clears a Test for Ovarian Cancer
Date:9/11/2009

Test can help identify potential malignancies, guide surgical decisions

SILVER SPRING, Md., Sept. 11 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today cleared a test that can help detect ovarian cancer in a pelvic mass that is already known to require surgery. The test, called OVA1, helps patients and health care professionals decide what type of surgery should be done and by whom.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

OVA1 identifies some women who will benefit from referral to a gynecological oncologist for their surgery, despite negative results from other clinical and radiographic tests for ovarian cancer. If other test results suggest cancer, referral to an oncologist is appropriate even with a negative OVA1 result.

OVA1 should be used by primary care physicians or gynecologists as an adjunctive test to complement, not replace, other diagnostic and clinical procedures.

OVA1 uses a blood sample to test for levels of five proteins that change due to ovarian cancer. The test combines the five separate results into a single numerical score between 0 and 10 to indicate the likelihood that the pelvic mass is benign or malignant.

OVA1 is intended only for women, 18 years and older, who are already selected for surgery because of their pelvic mass. It is not intended for ovarian cancer screening or for a definitive diagnosis of ovarian cancer. Interpreting the test result requires knowledge of whether the woman is pre- or post-menopausal.

The American College of Obstetricians and Gynecologists and the Society of Gynecologic Oncologists published recommendations in 2002 for the role of generalist obstetrician-gynecologists in the earl
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. U.S. Food and Drug Administration Clears Way for Multi-Center Clinical Trial of IDEV Technologies SUPERA Peripheral Stent
2. FDA Clears the Pathwork(R) Tissue of Origin Test for Hard-To-Identify Tumors
3. FDA Clears ExAblate Fertility Enhancement Study in Women With Uterine Fibroids
4. FDA Clears Advanced Test for Monitoring Metastatic Colorectal Cancer
5. Cancer Treatment Centers of America(R) Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells
6. Oasmia: FDA Grants Paclical(R) Orphan Drug Designation for Ovarian Cancer in the USA
7. Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results
8. Pivotal Data Published For First Biomarker Combination Test to Determine Risk of Ovarian Cancer in Women Who Present With Pelvic Mass
9. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
10. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
11. Abeome and Cato Research to Collaborate on Ovarian Cancer Therapeutic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Asterias Biotherapeutics Inc. (OTCBB: ASTY) has received ... to initiate a Phase 1/2a clinical trial of its ... injury.  The approved trial follows the successful completion of ... is designed to assess safety and activity of escalating ... cord injuries, the first targeted indication for AST-OPC1 and ...
(Date:8/26/2014)... STATESVILLE, N.C., Aug. 26, 2014  Kewaunee Scientific Corporation ... its first quarter ended July 31, 2014. ... sales of $32,003,000 in the first quarter last year. ... per diluted share, as compared to net earnings of ... quarter of the prior year. However, both sales and ...
(Date:8/26/2014)... 26, 2014 Research and Markets ... Meter Industry Report 2014 " report to their ... Report 2014 is a professional and in-depth study on ... The report provides a basic overview of ... structure. The glucose meter market analysis is provided for ...
Breaking Medicine Technology:Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 2Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 4Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 5Kewaunee Scientific Reports Results for First Quarter 2Kewaunee Scientific Reports Results for First Quarter 3Kewaunee Scientific Reports Results for First Quarter 4Kewaunee Scientific Reports Results for First Quarter 5Kewaunee Scientific Reports Results for First Quarter 6Global Glucose Meter Industry Report 2014 2Global Glucose Meter Industry Report 2014 3
(Date:8/27/2014)... Casey Diekman, assistant professor of mathematical sciences ... to gain greater insight into the biological clock that ... harmonized the behavior of humans and all other mammals ... of light and dark experienced each day and with ... related to natural patterns of sleep/wake behavior which, when ...
(Date:8/27/2014)... Time to Play Golf, a fast-growing ... , With 80-degree temperatures and only partially clouded skies, ... (TTPGolf) Inaugural Outing. Around 50 golfers showed up to duel ... beautiful Heron Glen Golf Course in Ringoes, New Jersey. , ... to be having a great time. Birdies were dropping and ...
(Date:8/27/2014)... August 27, 2014 President Obama is ... immigration. A White House initiative that supplies green ... undocumented immigrants would also open a pathway to Social ... , Access to work authorization would add new ... the program is the target of proposals to cut ...
(Date:8/27/2014)... The use of ESAs to treat ... may eliminate the need for blood transfusion and associated ... webinar, Dr. Zanhua Yi, board certified in hematology, oncology, ... necessity of erythropoiesis-stimulating agents (ESAs) in the treatment of ... Food and Drug Administration (FDA) has approved three ESAs ...
(Date:8/27/2014)... Michael A. Bottar has been ... Best Lawyers In America© for the practice areas of ... - Plaintiffs." , Bottar received his undergraduate degree from ... of Syracuse University College of Law where is an ... of the Syracuse Law Review Survey of New York ...
Breaking Medicine News(10 mins):Health News:NJIT Researcher Receives New NSF Funding to Study Fundamental Rhythms of Life 2Health News:NJIT Researcher Receives New NSF Funding to Study Fundamental Rhythms of Life 3Health News:NJIT Researcher Receives New NSF Funding to Study Fundamental Rhythms of Life 4Health News:Recap: Time To Play Golf Inaugural Golf Outing 2Health News:The Senior Citizens League (TSCL) Warns: White House Action On Immigration Could Give Social Security To Known Illegals 2Health News:AllMed Webinar Helps Health Plans Determine Medical Necessity Of ESAs In The Treatment Of Chronic Kidney Disease 2Health News:AllMed Webinar Helps Health Plans Determine Medical Necessity Of ESAs In The Treatment Of Chronic Kidney Disease 3Health News:Michael A. Bottar Selected For Inclusion In The Best Lawyers In America© 2015 2
... 25 - "We are excited about,the strong efforts in ... facility," said Judie Brown, president of American Life,League., ... nation,with 287 surgical and medical abortion facilities across the ... abortion operation in the,Denver suburb of Stapleton and local ...
... stem cells that differentiate into bone appears to cause regeneration ... strategy for osteoporosis, according to a report in the February ... by researchers from Massachusetts General Hospital (MGH) and the Harvard ... medication used to treat bone marrow cancer improved bone density ...
... while eating out in the New Year, SAN ... the New Year,s resolution list. But for the thousands ... is not always,easy. Today, American Express issued its Tastemaker ... best San Francisco restaurants where diners,can get a fresh, ...
... 25 3.5 million lives could be,saved over the ... and treatment measures in the 30 hardest hit countries ... the World Economic,Forum. Additionally, rapid scale-up would increase annual ... prevent 672 million malaria cases, and,free up 427,000 needed ...
... of teenagers may have metabolic syndrome, a clustering of risk ... and diabetes in adulthood. This shocking statistic represents some of ... in children and adolescents a necessary starting point for ... in youth than it has been in adults. , With ...
... Full Year 2007 Revenue of Approximately $154 million, Announces Full ... ... SAN DIEGO, Jan. 25 NuVasive, Inc. (Nasdaq:,NUVA), a medical ... for the spine, today announced,preliminary unaudited financial results for the ...
Cached Medicine News:Health News:Turning on adult stem cells may help repair bone 2Health News:Eating Healthy in the New Year? American Express Tastemakers Dish on the Top San Francisco Restaurants for Grabbing a Healthy Bite 2Health News:Eating Healthy in the New Year? American Express Tastemakers Dish on the Top San Francisco Restaurants for Grabbing a Healthy Bite 3Health News:Global Health and Business Leaders Announce 36-Month Effort to Expand Malaria Control in Africa; 3.5 Million Lives Could be Saved in Five Years, Study Finds 2Health News:Global Health and Business Leaders Announce 36-Month Effort to Expand Malaria Control in Africa; 3.5 Million Lives Could be Saved in Five Years, Study Finds 3Health News:Global Health and Business Leaders Announce 36-Month Effort to Expand Malaria Control in Africa; 3.5 Million Lives Could be Saved in Five Years, Study Finds 4Health News:Metabolic syndrome affects nearly 1 in 10 US teens 2Health News:Metabolic syndrome affects nearly 1 in 10 US teens 3Health News:NuVasive Announces Preliminary Unaudited Full Year 2007 Financial Results 2Health News:NuVasive Announces Preliminary Unaudited Full Year 2007 Financial Results 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: